The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Adalimumab in the therapy of uveitis in childhood
Open accessAbstract
PURPOSE: Chronic anterior uveitis in children often takes a serious course. Despite various immunosuppressive drugs some children do not respond sufficiently and there is a high risk of them becoming seriously disabled. Anti-TNF alpha therapy has been shown by our group and others to be mostly ineffective (Etanercept) or partly effective (Infliximab) with the risk of anaphylactic reactions. Here we report on 18 young patients treated with Adalimumab (Humira), a complete humanised anti-TNF alpha antibody. METHODS: We retrospectively analysed 18 patients, who were treated with Adalimumab (20-40 mg, every 2 weeks, when ineffective every week); 17 had juvenile idiopathic arthritis, one was without detectable underlying disease. The age at onset of arthritis varied from 0.5-15 years and for uveitis from 2-19 years. Patients were included when the previous anti-inflammatory therapy had been ineffective. It consisted of systemic steroids (n = 18), Cyclosporin A (n = 18), Methotrexate (n = 18), Azathioprine (n = 12), Mycophenolate mofetil (n = 4), Cyclophosphamide (n = 2), Leflunomide (n = 3), Etanercept (n = 8) and Infliximab (n = 5). The grading for uveitis was: (a) effective: no relapse or more than two relapses less than before treatment, (b) mild: one relapse less than before treatment, (c) no response: no change in relapse rate and (d) worsening: more relapses under treatment than before. The grading for arthritis (depending on the clinical findings), using three out of six parameters of the ACR PED Criteria, was: effective, mild, no response, worsening. RESULTS: For arthritis (n = 16) the response to Adalimumab was effective in 10 of 16 patients, mild in three patients, three did not respond. For uveitis (n = 18) Adalimumab was effective in 16, mild in one child, and one patient did not show any effect. After a very good response initially a shorter application time had to be used to maintain the good anti-inflammatory effect in one child. Additional immunosuppressive treatment was used in seven of the effectively treated children. Due to elevation of liver enzymes in one patient, who also took MTX, Adalimumab had to be discontinued. No anaphylactic reactions or increased frequency of infections since start of Adalimumab treatment was reported. CONCLUSIONS: For our group of children with long lasting disease our results show that Adalimumab was effective or mildly effective against the arthritis in 81%, but in uveitis in 88%. While these results regarding arthritis are comparable with other TNF-alpha blocking drugs (Etanercept), Adalimumab seems to be much more effective against uveitis than Etanercept. Anaphylactic reactions, found in a previous study from our group after Infliximab treatment, were not seen with Adalimumab. The necessary dosage and the treatment period, which probably have to be defined individually for each patient, remain unclear.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.03.057 · Cited by 4,396
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., Jackson, C. G., Lange, M., & Burge, D. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400401 · Cited by 2,085
Weinblatt, M. E., Keystone, E. C., Furst, D. E., Moreland, L. W., Weisman, M. H., Birbara, C. A., Teoh, L. A., Fischkoff, S. A., & Chartash, E. K. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10697 · Cited by 1,757
Klareskog, L., van der Heijde, D., de Jager, J. P., Gough, A., Kalden, J., Malaise, M., Mola, E. M., Pavelka, K., Sany, J., Settas, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15640-7 · Cited by 1,751
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Etanercept in Children with Polyarticular Juvenile Rheumatoid Arthritis
Lovell, D. J., Giannini, E. H., Reiff, A., Cawkwell, G. D., Silverman, E. D., Nocton, J. J., Stein, L. D., Gedalia, A., Ilowite, N. T., Wallace, C. A., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003163421103 · Cited by 1,246
Keystone, E. C., Kavanaugh, A. F., Sharp, J. T., Tannenbaum, H., Hua, Y., Teoh, L. S., Fischkoff, S. A., & Chartash, E. K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20217 · Cited by 1,172
Preliminary definition of improvement in juvenile arthritis
Giannini, E. H., Ruperto, N., Ravelli, A., Lovell, D. J., Felson, D. T., & Martini, A. (1997) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199707)40:7<1202::aid-art3>3.0.co;2-r · Cited by 1,047
Infections in patients with rheumatoid arthritis treated with biologic agents
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova‐Scholz, M., Gromnica‐Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21386 · Cited by 681
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists
Scallon, B., Cai, A., Solowski, N., Rosenberg, A., Song, X.-Y., Shealy, D., & Wagner, C. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.301.2.418 · Cited by 672
van de Putte, L. B. A., Atkins, C., Malaise, M., Sany, J., Russell, A. S., van Riel, P. L. C. M., Settas, L., Bijlsma, J. W., Todesco, S., Dougados, M., et al. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2003.013052 · Cited by 617
Lügering, A., Schmidt, M., Lügering, N., Pauels, H.-G., Domschke, W., & Kucharzik, T. (2001) · Gastroenterology · doi:10.1053/gast.2001.28702 · Cited by 588
Furst, D. E., Schiff, M. H., Fleischmann, R., Strand, V., Birbara, C. A., Compagnone, D., Fischkoff, S. A., & Chartash, E. (2003) · PubMed · Cited by 495
Quartier, P., Taupin, P., Bourdeaut, F., Lemelle, I., Pillet, P., Bost, M., Sibilia, J., Koné‐Paut, I., Gandon‐Laloum, S., LeBideau, M., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10885 · Cited by 364
Ohno, S., Nakamura, S., Hori, S., Shimakawa, M., Kawashima, H., Mochizuki, M., Sugita, S., Ueno, S., Yoshizaki, K., & 稲葉, 午. (2004) · PubMed · Cited by 343
Smith, J. A., Thompson, D. J. S., Whitcup, S. M., Suhler, E., Clarke, G., Smith, S., Robinson, M., Kim, J., & Barron, K. S. (2005) · Arthritis Care & Research · doi:10.1002/art.20904 · Cited by 308
Suhler, E. B. (2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.7.903 · Cited by 306
Weisman, M. H., Moreland, L. W., Furst, D. E., Weinblatt, M. E., Keystone, E. C., Paulus, H. E., Teoh, L. S., Velagapudi, R. B., Noertersheuser, P. A., Granneman, G. R., et al. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80164-9 · Cited by 303
Etanercept therapy in children with treatment-resistant uveitis
Reiff, A., Takei, S., Sadeghi, S., Stout, A., Shaham, B., Bernstein, B., Gallagher, K., & Stout, T. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200106)44:6<1411::aid-art235>3.0.co;2-o · Cited by 298
Aqueous Humor and Serum Tumor Necrosis Factor-α in Clinical Uveitis
Santos Lacomba, M., Marcos Martín, C., Gallardo Galera, J. M., Gómez Vidal, M. A., Collantes Estévez, E., Ramírez Chamond, R., & Omar, M. M. (2001) · Ophthalmic Research · doi:10.1159/000055677 · Cited by 296
Lovell, D. J., Giannini, E. H., Reiff, A., Jones, O. Y., Schneider, R., Olson, J. C., Stein, L. D., Gedalia, A., Ilowite, N. T., Wallace, C. A., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10710 · Cited by 250
Infliximab for Recurrent, Sight-Threatening Ocular Inflammation in Adamantiades–Behçet Disease
Sfikakis, P. P., Kaklamanis, P. H., Elezoglou, A., Katsilambros, N., Theodossiadis, P. G., Papaefthimiou, S., & Markomichelakis, N. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00025 · Cited by 229
Efficacy of Etanercept in Preventing Relapse of Uveitis Controlled by Methotrexate
Foster, C. S. (2003) · Archives of Ophthalmology · doi:10.1001/archopht.121.4.437 · Cited by 213
Favorable Response to High-Dose Infliximab for Refractory Childhood Uveitis
Kahn, P., Weiss, M., Imundo, L. F., & Levy, D. M. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.01.005 · Cited by 210
den Broeder, A. A., van de Putte, L., Rau, R., Schattenkirchner, M., van Riel, P. L. C. M., Sander, O., Binder, C., Fenner, H., Bankmann, Y., Velagapudi, R. B., et al. (2002) · PubMed · Cited by 195
Tumor necrosis factor α blockade with infliximab for refractory uveitis and scleritis
Murphy, C. C., Ayliffe, W. H., Booth, A., Makanjuola, D., Andrews, P. A., & Jayne, D. (2004) · Ophthalmology · doi:10.1016/s0161-6420(03)00721-8 · Cited by 188
de Vos, A. F., Haren, M. A. C. V., Verhagen, C., Hoekzema, R., & Kijlstra, A. (1994) · PubMed · Cited by 185
Autoimmune thyroid disease in systemic lupus erythematosus
Pyne, D., & Isenberg, D. A. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.1.70 · Cited by 173
Etanercept and uveitis in patients with juvenile idiopathic arthritis
Schmeling, H., & Horneff, G. (2005) · Rheumatology · doi:10.1093/rheumatology/keh658 · Cited by 169
Anti-TNF- therapy for sight threatening uveitis
Lindstedt, E. W. (2005) · British Journal of Ophthalmology · doi:10.1136/bjo.2003.037192 · Cited by 168
Koizumi, K., Poulaki, V., Doehmen, S., Welsandt, G., Radetzky, S., Lappas, A., Kociok, N., Kirchhof, B., & Joussen, A. M. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0589 · Cited by 160
Rau, R. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii70 · Cited by 159
Infliximab for chronic cystoid macular edema associated with uveitis
Markomichelakis, N. N., THEODOSSIADIS, P. G., Pantelia, E., Papaefthimiou, S., THEODOSSIADIS, G. P., & Sfikakis, P. P. (2004) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2004.04.066 · Cited by 155
Ocular inflammatory effects of intravitreally-injected tumor necrosis factor.
Rosenbaum, J. T., Howes, E. L., Rubin, R. M., & Samples, J. R. (1988) · PubMed Central · Cited by 148
Does etanercept induce uveitis?
Reddy, A. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.7.925 · Cited by 121
Dick, A. D., Duncan, L., Hale, G., Waldmann, H., & Isaacs, J. D. (1998) · Journal of Autoimmunity · doi:10.1006/jaut.1998.0197 · Cited by 116
Mycophenolate mofetil in the treatment of uveitis in children
Doycheva, D., Deuter, C., Stuebiger, N., Biester, S., & Zierhut, M. (2007) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.094698 · Cited by 106
Self-citationDifferentiating the efficacy of the tumor necrosis factor inhibitors
Haraoui, B. P. (2005) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.01.003 · Cited by 95
New Indications for Treatment of Chronic Inflammation by TNF-α Blockade
Kaplan, N. M., Palmer, B. F., & Reimold, A. M. (2003) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200302000-00005 · Cited by 93
Robertson, M., Liversidge, J., Forrester, J. V., & Dick, A. D. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-1156 · Cited by 89
Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab
Fries, W., Giofré, M. R., Catanoso, M., & Gullo, R. L. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05514.x · Cited by 85
Ocular inflammatory effects of intravitreally injected tumor necrosis factor-alpha and endotoxin
Fleisher, L. N., Ferrell, J., & McGahan, M. C. (1990) · Inflammation · doi:10.1007/bf00915816 · Cited by 73
Infliximab for the Treatment of Posterior Uveitis with Retinal Neovascularization in Behçet Disease
Giansanti, F., Barbera, M. L., Virgili, G., Pieri, B., Emmi, L., & Menchini, U. (2004) · European Journal of Ophthalmology · doi:10.1177/112067210401400515 · Cited by 65
Greiner, K. H., Murphy, C. C., Willermain, F., Duncan, L., Plskova, J., Hale, G., Isaacs, J. D., Forrester, J. V., & Dick, A. D. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.03-0659 · Cited by 57
Etanercept treatment in the endotoxin-induced uveitis of rats
Avunduk, M. C., Avunduk, A. M., Menevşe, E., Baltacı, A. K., Özyazgan, Y., & Mogolkoc, R. (2004) · Experimental Eye Research · doi:10.1016/j.exer.2004.06.001 · Cited by 47
de Vos, A. F., Haren, M. A. C. V., Verhagen, C., Hoekzema, R., & Kijlstra, A. (1995) · Experimental Eye Research · doi:10.1016/s0014-4835(95)80011-5 · Cited by 40
van Rijthoven, A. W. A. M., Bijlsma, J. W. J., van Dijk, M. R., Derksen, R. H. W. M., & van Roon, J. A. G. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kel227 · Cited by 37
The treatment of recurrent uveitis with TNFα inhibitors
Falappone, P. C. F., Iannone, F., Scioscia, C., Grattagliano, V., Covelli, M., & Lapadula, G. (2011) · Reumatismo · doi:10.4081/reumatismo.2004.185 · Cited by 16
Cited by
Extraintestinal Manifestations of Inflammatory Bowel Disease
Vavricka, S. R., Schoepfer, A., Scharl, M., Lakatos, P. L., Navarini, A., & Rogler, G. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000392 · Cited by 909
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Levy-Clarke, G., Jabs, D. A., Read, R. W., Rosenbaum, J. T., Vitale, A., & Van Gelder, R. N. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.048 · Cited by 483
Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis
Ramanan, A. V., Dick, A. D., Jones, A. P., McKay, A., Williamson, P. R., Compeyrot-Lacassagne, S., Hardwick, B., Hickey, H., Hughes, D., Woo, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614160 · Cited by 437
Do tumor necrosis factor inhibitors cause uveitis? A registry‐based study
Lim, L. L., Fraunfelder, F. W., & Rosenbaum, J. T. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22918 · Cited by 315
Metadata
- Authors
- Biester, S., Deuter, C., Michels, H., Haefner, R., Kuemmerle-Deschner, J., Doycheva, D., & Zierhut, M.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2006-10-11
- Volume
- 91
- Issue
- 3
- Pages
- 319-324
- ISSN
- 0007-1161 (ISSN-L)
- OpenAlex
- W2135325634
- Cited by
- 294
- References
- 51
- FWCI
- 16.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.